-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 21, the Anhui Province Pharmaceutical Centralized Procurement Platform issued the "Notice on Prohibiting the Publication of Certain Drug Catalogues" and the list
It is worth noting that the paroxetine hydrochloride enteric-coated sustained-release tablets with the relevant serial number in the above list are listed
.
It is reported that this product was launched by GSK as a new dosage form of enteric-coated sustained-release tablets in China in 2012, and entered the national medical insurance as one of the newly-added sustained-release dosage forms of medical insurance negotiations in 2017, and product sales have rapidly increased
In addition, most of the drugs in the above list are injections, such as recombinant human granulocyte stimulating factor injection and Shengmai injection
.
It is understood that in March 2020, in the "New Coronavirus Pneumonia Diagnosis and Treatment Plan" (trial version 7) issued by the National Health Commission, Shengmai injection continues to be selected as the recommended Chinese patent medicine in the diagnosis and treatment plan for the treatment of critically ill patients.
(Internal closure and external exclusion) Patients .
Shengmai injection is derived from the classic prescription "Shengmai San", and currently there are 8 main manufacturers, namely Suzhong Pharmaceutical Group, Shanxi Taihang Pharmaceutical, Sichuan Sichuan University Huaxi Pharmaceutical, and Ji'an Yisheng Pharmaceutical in Jilin Province Co.
, Ltd.
, Shanghai Hutchison Pharmaceutical and other .
According to data from the Food and Drug Administration, there are 25 production approvals for Shengmai Injection .
From the perspective of the competitive landscape, among the eight companies of Shengmai Injection, China Resources (39) Ya'an Pharmaceutical and Suzhong Pharmaceutical have jointly divided up 90% of the market, showing a trend of dual-role development .
The fifth batch of national sourcing will open bids on June 23.
Injections have become the “biggest buyer” of this centralized sourcing.
29 of the 58 varieties are injections, which is more than the sum of the previous centralized sourcing injections, involving multiple major issues.
Pound product .
According to statistics, the purchase amount of these 58 varieties in the first year × the purchase amount of the highest effective quotation is 56.
24 billion yuan .
There has always been no shortage of injections in relevant announcements on the procurement platform .
On June 16, the Jiangxi Province Pharmaceutical Procurement Service Platform issued an announcement to suspend the procurement qualifications of some drugs .
If the number of generic drugs that have passed the consistency evaluation of the online drug exceeds 3, under the premise of ensuring the supply, the centralized procurement will no longer select products that have not passed the consistency evaluation, and the procurement qualification will be restored after the consistency evaluation; June 21 Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Announcement of the List of Drugs Listed on the Internet in April 2021 with a Larger Purchase List of Drugs with a Larger Bargaining Price Beyond the "Yellow Line"".
19 drugs were named due to price issues, and all injections were blocked.
Involved .
The injection market will shrink by a large margin.
After the market shrinks, only injections that are compliant and have solid and strong clinical evidence will remain, and clinical non-standard use will be intensively monitored .
The value of the first generic drug is highlighted
It is worth noting that the paroxetine hydrochloride enteric-coated sustained-release tablets with the relevant serial number in the above list are listed
.
It is reported that this product was launched by GSK as a new dosage form of enteric-coated sustained-release tablets in China in 2012, and entered the national medical insurance as one of the newly-added sustained-release dosage forms of medical insurance negotiations in 2017, and product sales have rapidly increased
Strict compliance requirements everywhere
In addition, most of the drugs in the above list are injections, such as recombinant human granulocyte stimulating factor injection and Shengmai injection
.
It is understood that in March 2020, in the "New Coronavirus Pneumonia Diagnosis and Treatment Plan" (trial version 7) issued by the National Health Commission, Shengmai injection continues to be selected as the recommended Chinese patent medicine in the diagnosis and treatment plan for the treatment of critically ill patients.
(Internal closure and external exclusion) Patients .
Shengmai injection is derived from the classic prescription "Shengmai San", and currently there are 8 main manufacturers, namely Suzhong Pharmaceutical Group, Shanxi Taihang Pharmaceutical, Sichuan Sichuan University Huaxi Pharmaceutical, and Ji'an Yisheng Pharmaceutical in Jilin Province Co.
, Ltd.
, Shanghai Hutchison Pharmaceutical and other .
According to data from the Food and Drug Administration, there are 25 production approvals for Shengmai Injection .
From the perspective of the competitive landscape, among the eight companies of Shengmai Injection, China Resources (39) Ya'an Pharmaceutical and Suzhong Pharmaceutical have jointly divided up 90% of the market, showing a trend of dual-role development .
The fifth batch of national sourcing will open bids on June 23.
Injections have become the “biggest buyer” of this centralized sourcing.
29 of the 58 varieties are injections, which is more than the sum of the previous centralized sourcing injections, involving multiple major issues.
Pound product .
According to statistics, the purchase amount of these 58 varieties in the first year × the purchase amount of the highest effective quotation is 56.
24 billion yuan .
There has always been no shortage of injections in relevant announcements on the procurement platform .
On June 16, the Jiangxi Province Pharmaceutical Procurement Service Platform issued an announcement to suspend the procurement qualifications of some drugs .
If the number of generic drugs that have passed the consistency evaluation of the online drug exceeds 3, under the premise of ensuring the supply, the centralized procurement will no longer select products that have not passed the consistency evaluation, and the procurement qualification will be restored after the consistency evaluation; June 21 Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Announcement of the List of Drugs Listed on the Internet in April 2021 with a Larger Purchase List of Drugs with a Larger Bargaining Price Beyond the "Yellow Line"".
19 drugs were named due to price issues, and all injections were blocked.
Involved .
The injection market will shrink by a large margin.
After the market shrinks, only injections that are compliant and have solid and strong clinical evidence will remain, and clinical non-standard use will be intensively monitored .
